1. Catalog
  2. ORN Fall 2023 - Brixadi (buprenorphine-XR) for the ...
Image For Activity Cover
ORN Fall 2023 - Brixadi (buprenorphine-XR) for the Treatment of Opioid Use Disorder
AVAILABLE ON-DEMAND
Available on-demand. Login or create an account to register to view the recording.
Description:
During this lecture participants will learn how to treat patients with opioid use disorder using the newly FDA-approved injectable formulation of buprenorphine, Brixadi.
Learning Objectives:
At the conclusion of this seminar, participants will be able to:
  1. Discuss how to start patients with OUD on Brixadi
  2. Adjust the dose to alleviate opioid withdrawal, suppress cravings and use of opioids
  3. Name typical adverse effects of the medication
  4. Describe how the medication is to be administered and possible sites for injection
Claim Credits & Course Materials

How to claim your credits & download handouts for each webinar:

Under the "Course" tab (or "Content" tab):
  1. Complete the required course materials.
  2. Claim your credits by clicking the "Report Credit" or "Request Credit" button on the right above the course materials.
Speaker:
Antoine Douaihy, MD

Dr. Douaihy is a Professor of Psychiatry and Medicine, Senior Academic Director of Addiction Medicine Services (AMS) and Addiction Psychiatry Fellowship at Western Psychiatric Hospital of the University of Pittsburgh Medical Center (UPMC), and Co-Director of the Tobacco Treatment Service of UPMC. His areas of clinical and research expertise and interest are substance use disorders (SUDs) and SUDs co­ occurring with psychiatric disorders in adults and adolescents, psychiatric disorders in individuals with HIV/HCV, smoking cessation and psychosocial approaches, particularly motivational interviewing, and medication trials for co-occurring disorders, opioid and stimulant use disorders. He has a demonstrated record of expertise and experience in SUDs and a well-established record of leadership and expertise in conducting multi-site clinical trials. He has served as Principal Investigator (Pl), Co-I, or a consultant on studies funded by NIAAA, NIDA, NIMH, AFSP, NHLBI, HRSA, SAMHSA, and pharmaceutical industries. He served as a member of the Opioid Addiction Task Force (established by the U.S. District Attorney in Allegheny County) and the opioid addiction and recovery task force at the University of Pittsburgh. He is currently the vice chair of Pittsburgh HIV Commission and a member of the physician work group on medical marijuana at the PA Department of Health. 
Summary
Availability: No future session
Expires on Dec 31, 2024
Cost: FREE
Credit Offered:
1 AOA Category 1A Credit
Create Account
Recommended
Powered By